DMAC - DiaMedica Therapeutics Inc.
IEX Last Trade
5.385
-0.045 -0.836%
Share volume: 916
Last Updated: Thu 26 Dec 2024 08:30:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$5.43
-0.05
-0.83%
Fundamental analysis
22%
Profitability
25%
Dept financing
5%
Liquidity
50%
Performance
16%
Performance
5 Days
-2.14%
1 Month
3.54%
3 Months
22.33%
6 Months
77.70%
1 Year
85.87%
2 Year
243.79%
Key data
Stock price
$5.38
DAY RANGE
$5.21 - $5.45
52 WEEK RANGE
$2.29 - $6.41
52 WEEK CHANGE
$80.76
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Rick J. Pauls
Region: US
Website: diamedica.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: diamedica.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
DiaMedica Therapeutics Inc. develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein. DM199 is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes.
Recent news